Virtual Library
Start Your Search
J. Zhao
Author of
-
+
Best abstracts selected from submissions 7 (ID 5)
- Event: ACLC 2018
- Type: Oral Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/09/2018, 16:20 - 17:00, Jade Ballroom
-
+
OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (ID 67)
16:20 - 17:00 | Author(s): J. Zhao
- Abstract
Background:
Non-small cell lung cancer (NSCLC) can acquire resistance to EGFR tyrosine kinase inhibitors (EGFR TKIs) via MET activation; dual MET/EGFR inhibition may have potential in EGFR TKI-resistant NSCLC. Tepotinib is a potent, selective MET TKI. We report randomized phase 2 data from a phase 1b/2 signal detection trial of tepotinib+gefitinib vs chemotherapy (pemetrexed + cisplatin/carboplatin) in patients with MET+/EGFR+T790M- NSCLC (NCT01982955).
Method:
Asian patients with advanced MET+ (IHC2+, IHC3+, gene amplification) NSCLC, acquired resistance to 1st-line EGFR TKI and ECOG performance status 0